Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
3.26 ^USD	+0.93%		+9.03%	-24.71%

02/06	Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)	CI
17/05	Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial	RE

Fredric N. Eshelman Demands Apology and Retraction of Puma Biotechnology’s Investor Presentation

January 28, 2016 at 03:19 am IST

On January 22, 2016, Puma Biotechnology, Inc. received a letter, dated January 20, 2016 from Fredric N. Eshelman, which demanded “an immediate apology and retraction of the Company's investor presentation” and threatened to proceed with legal action against the Company if the investor presentation is not retracted and an immediate apology is not provided.

Latest news about Puma Biotechnology, Inc.

Puma Biotechnology, Inc. Announces Presentation of Findings from A Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (Tbcrc 041)	02/06	CI
Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial	18/05	RE
Transcript : Puma Biotechnology, Inc., Q1 2024 Earnings Call, May 02, 2024	03/05
Puma Biotechnology, Inc. Provides Earnings Guidance for the Second Quarter of Full Year of 2024	03/05	CI
Puma Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise	20/03	MT
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	20/03	CI
Puma Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/03	CI
Transcript : Puma Biotechnology, Inc., Q4 2023 Earnings Call, Feb 29, 2024	01/03
Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	01/03	CI
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q4 EPS $0.31, vs. Street Est of $0.37	01/03	MT
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	01/03	CI
Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	13/02	CI
Puma Biotechnology, Inc. Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	11/12	CI
Transcript : Puma Biotechnology, Inc., Q3 2023 Earnings Call, Nov 02, 2023	03/11
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q3 EPS $0.17, vs. Street Est of $0.14	03/11	MT
Puma Biotechnology, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023	03/11	CI
Puma Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11	CI
Puma Biotechnology, Inc. Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting	14/23/14	CI
North American Morning Briefing : Stock Futures Edge Higher as PMI Data Awaited	22/23/22	DJ
Puma Biotechnology Gets FDA Orphan Drug Designation For Alisertib	22/23/22	MT
Puma Biotechnology Stock Up 6.9% on New FDA Orphan Drug Designation	22/23/22	DJ
Puma Biotechnology Gets Orphan Designation for Small Cell Lung Cancer Drug	22/23/22	DJ
FDA Clears Puma Biotechnology to Begin Mid-Stage Trial in Small Cell Lung Cancer	08/23/08	MT
Puma Biotechnology, Inc. Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer	08/23/08	CI

Chart Puma Biotechnology, Inc.

Duration

Period

More charts

Company Profile

Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Puma Biotechnology, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3.26 USD

Average target price

4.333 USD

Spread / Average Target

+32.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PUMA BIOTECHNOLOGY, INC.	-24.71%	16Cr
MODERNA, INC.	+19.41%	4.55TCr
IQVIA HOLDINGS INC.	-8.62%	3.85TCr
LONZA GROUP AG	+38.65%	3.81TCr
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	3.07TCr
CELLTRION, INC.	-13.50%	2.6TCr
ICON PUBLIC LIMITED COMPANY	+10.74%	2.59TCr
UNITED THERAPEUTICS CORPORATION	+44.87%	1.41TCr
MEDPACE HOLDINGS, INC.	+34.36%	1.27TCr
BIO-TECHNE CORPORATION	-7.14%	1.13TCr

Other Biotechnology & Medical Research